| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ... The Lancet 393 (10167), 156-167, 2019 | 1338 | 2019 |
| Synthetic lethal metabolic targeting of cellular senescence in cancer therapy JR Dörr, Y Yu, M Milanovic, G Beuster, C Zasada, JHM Däbritz, J Lisec, ... Nature 501 (7467), 421-425, 2013 | 567 | 2013 |
| Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the … AJM Ferreri, K Cwynarski, E Pulczynski, M Ponzoni, M Deckert, LS Politi, ... The Lancet Haematology 3 (5), e217-e227, 2016 | 528 | 2016 |
| PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin … P Borchmann, H Goergen, C Kobe, A Lohri, R Greil, DA Eichenauer, ... The Lancet 390 (10114), 2790-2802, 2017 | 363 | 2017 |
| Targeting of hematopoietic progenitor cells with MR contrast agents HE Daldrup-Link, M Rudelius, RAJ Oostendorp, M Settles, G Piontek, ... Radiology 228 (3), 760-767, 2003 | 315 | 2003 |
| Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS … AJM Ferreri, K Cwynarski, E Pulczynski, CP Fox, E Schorb, P La Rosée, ... The Lancet Haematology 4 (11), e510-e523, 2017 | 308 | 2017 |
| First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary … K Herrmann, M Schottelius, C Lapa, T Osl, A Poschenrieder, H Hänscheid, ... Journal of nuclear medicine 57 (2), 248-251, 2016 | 251 | 2016 |
| BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma J Bhadury, LM Nilsson, S Veppil Muralidharan, LC Green, Z Li, ... Proceedings of the National Academy of Sciences 111 (26), E2721-E2730, 2014 | 250 | 2014 |
| Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state J Den Hollander, S Rimpi, JR Doherty, M Rudelius, A Buck, A Hoellein, ... Blood, The Journal of the American Society of Hematology 116 (9), 1498-1505, 2010 | 250 | 2010 |
| Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation JA Nilsson, UB Keller, TA Baudino, C Yang, S Norton, JA Old, LM Nilsson, ... Cancer cell 7 (5), 433-444, 2005 | 223 | 2005 |
| In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma K Philipp‐Abbrederis, K Herrmann, S Knop, M Schottelius, M Eiber, ... EMBO molecular medicine 7 (4), 477-487, 2015 | 212 | 2015 |
| Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a … V Poeschel, G Held, M Ziepert, M Witzens-Harig, H Holte, L Thurner, ... The Lancet 394 (10216), 2271-2281, 2019 | 201 | 2019 |
| Positron emission tomography–guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German … M Fuchs, H Goergen, C Kobe, G Kuhnert, A Lohri, R Greil, S Sasse, ... Journal of clinical oncology 37 (31), 2835-2845, 2019 | 195 | 2019 |
| Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging HJ Wester, U Keller, M Schottelius, A Beer, K Philipp-Abbrederis, ... Theranostics 5 (6), 618, 2015 | 190 | 2015 |
| Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity R Eichner, M Heider, V Fernández-Sáiz, F van Bebber, AK Garz, ... Nature medicine 22 (7), 735-743, 2016 | 178 | 2016 |
| c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL KH Maclean, UB Keller, C Rodriguez-Galindo, JA Nilsson, JL Cleveland Molecular and cellular biology, 2003 | 173 | 2003 |
| Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model H Jespersen, MF Lindberg, M Donia, EMV Söderberg, R Andersen, ... Nature communications 8 (1), 707, 2017 | 167 | 2017 |
| Endothelial‐like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction I Ott, U Keller, M Knoedler, KS Götze, K Doss, P Fischer, K Urlbauer, ... The FASEB journal 19 (8), 992-994, 2005 | 163 | 2005 |
| High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study) K Fritsch, B Kasenda, E Schorb, P Hau, J Bloehdorn, R Möhle, S Loew, ... Leukemia 31 (4), 846-852, 2017 | 154 | 2017 |
| High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial G Illerhaus, B Kasenda, G Ihorst, G Egerer, M Lamprecht, U Keller, ... The Lancet Haematology 3 (8), e388-e397, 2016 | 152 | 2016 |
